Abeona Signs a License and Inventory Purchase Agreements with Taysha for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)
Shots:
- Abeona to receive $7M including $3M up front- $4M inventory purchase price- including GMP-sourced CLN1 plasmid and is eligible to receive $56M as clinical- regulatory- and commercial milestones along with royalties on sales of ABO-202
- Taysha gets an exclusive WW right to IP developed by scientists at the UNC and Abeona and Abeona know-how relating to the research- development- and manufacture of ABO-202. Abeona will continue the development of the P-I/II clinical trial protocol and manufacturing process and has received FDA clearance of its IND application that is anticipated to enter the clinic in 2021
- ABO-202 is a novel- one-time gene therapy for CLN1 disease- designed to deliver a functional copy of the PPT1 gene and has received the US FDA’s ODD- RPD and EMA’s OMPD
Click here to read full press release/ article | Ref: Abeona Therapeutics | Image: Pexel
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com